NCT07337577 · Brigham and Women's Hospital
Targeted Artificial Intelligence Language mOdel Recommendations for Heart Failure (TAILOR-HF)
(TAILOR-HF)
What this study is about
This study is an investigator-initiated, cluster-randomly assigned implementation trial evaluating a large language model (LLM)-based clinical decision support (CDS) tool designed to improve guideline-directed medical therapy (GDMT) for adult patients with heart failure seen in outpatient cardiology clinics at Mass General Brigham.
View original scientific description
This study is an investigator-initiated, cluster-randomized implementation trial evaluating a large language model (LLM)-based clinical decision support (CDS) tool designed to improve guideline-directed medical therapy (GDMT) for adult patients with heart failure seen in outpatient cardiology clinics at Mass General Brigham. For eligible heart failure encounters, the CDS tool reviews existing electronic health record (EHR) data, including diagnoses, medications, vital signs, laboratory results, and recent notes, and generates brief, clinician-facing messages suggesting opportunities to initiate or optimize GDMT and highlighting relevant safety considerations. Messages are delivered to cardiology providers via Epic InBasket and/or institutional email prior to scheduled visits. The tool is advisory only and cannot place orders or change medications automatically; all treatment decisions remain at the discretion of the treating clinician and patient. Cardiology providers are assigned at the provider/clinic level to early implementation of the CDS tool versus usual care (no messages) during the initial phase. The primary outcome is GDMT optimization within 30 days of an index visit. Secondary outcomes include feasibility of CDS generation and delivery and a 30-day safety composite (e.g., heart failure hospitalization, acute kidney injury, hyperkalemia, hypotension or bradyarrhythmia plausibly related to GDMT).
Interventions
DEVICE
LLM-GDMT Clinical Decision Support Tool
Software-only, large language model-based clinical decision support tool that reviews structured and unstructured EHR data for adult heart failure patients and generates brief, clinician-facing messages suggesting opportunities to initiate or optimize guideline-directed medical therapy (GDMT) and highlighting relevant safety considerations. Messages are delivered to cardiology providers via Epic InBasket and/or institutional email prior to eligible outpatient visits. The tool is advisory only and cannot place orders or directly change medications; all treatment decisions remain at the discretion of the treating clinician and patient.
Primary outcome measures
Any GDMT optimization within 30 days of index visit
Time frame: 30 days
Among eligible HF encounters, the proportion with initiation of at least one new GDMT class not previously prescribed and/or uptitration of at least one existing GDMT medication during or within 30 days after the index visit, comparing early-implementation vs usual care arms.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Age ≥18 years
- Scheduled outpatient visit with a participating cardiology provider in an MGB outpatient cardiology clinic
- At least one prior cardiology clinic visit in the MGB system within the past 2 years
- Diagnosis of heart failure by ICD code within the past 2 years
- Heart failure diagnosis supported by at least one of the following:
- Current or recent use of a loop diuretic
- Left ventricular ejection fraction ≤40% on the most recent echocardiogram
- Explicit documentation of heart failure diagnosis or heart failure signs/symptoms in a prior cardiology note
Exclusion criteria
- Systolic blood pressure \<90 mmHg on the most recent recorded measurement
- Heart rate \<50 beats per minute on the most recent recorded measurement
- eGFR \<20 mL/min/1.73 m² on the most recent laboratory assessment
- Known cardiac amyloidosis or hypertrophic cardiomyopathy
- History of heart transplant or presence of a left ventricular assist device
- Severe aortic stenosis, severe aortic insufficiency, or severe mitral stenosis on the most recent echocardiogram
- Encounter occurs in an adult congenital heart disease clinic
Where
- Boston, Massachusetts
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Aug 31, 2026 · Source of record for eligibility and locations